---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-212606"
form_type: "8-K"
ticker: null
cik: "0001305253"
company_name: "Eiger BioPharmaceuticals, Inc."
filed_at: "2024-09-04T23:59:59+00:00"
generated_at: "2026-05-31T06:23:57.712056+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Eiger sells lonafarnib ($5.2M) and peginterferon lambda ($1M) assets in Ch11; closings Sept 3

## Summary
- Bankruptcy Court approved both asset sales on August 20, 2024; closings occurred September 3, 2024.
- Lonafarnib antiviral assets sold to Eiger InnoTherapeutics for $5.2M plus cure costs and assumed liabilities.
- Peginterferon lambda-1a assets sold to same buyer for $1.0M plus cure costs and assumed liabilities.
- Company warns securityholders may face significant or total loss on investment given Chapter 11 outcome.

## SEC filing metadata
- accession: 0001193125-24-212606
- form_type: 8-K
- cik: 0001305253
- company_name: Eiger BioPharmaceuticals, Inc.
- filed_at: 2024-09-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1305253/000119312524212606/0001193125-24-212606-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1305253/000119312524212606/d889209d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-212606
- JSON: https://secwatch.observer/filing/0001193125-24-212606.json
- Plain text: https://secwatch.observer/filing/0001193125-24-212606.txt

## Key facts
- M&A Transactions
  Eiger BioPharmaceuticals, Inc. completed a disposition involving Eiger InnoTherapeutics, Inc. for $5.2 million (closed 2024-09-03).
  - Action: disposition
  - Counterparty: Eiger InnoTherapeutics, Inc.
  - Consideration: $5.2 million
  - Closing: 2024-09-03
  source text: Lonafarnib Antiviral Asset Sale On August 1, 2024, the Company and Eiger InnoTherapeutics, Inc. (the “ Purchaser ”) entered into that certain Lonafarnib Asset Purchase Agreement, pursuant to which the Purchaser agreed to acquire all of the Company’s rights, title and interests in, to and under the assets and interests used in the business related to the development, manufacture and commercialization of certain lonafarnib antiviral products for $5.2 million, plus a portion of the cure costs with respect to assigned contracts and the assumption of specified liabilities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1305253/000119312524212606/0001193125-24-212606-index.htm
- M&A Transactions
  Eiger BioPharmaceuticals, Inc. completed a disposition involving Eiger InnoTherapeutics, Inc. for $1.0 million (closed 2024-09-03).
  - Action: disposition
  - Counterparty: Eiger InnoTherapeutics, Inc.
  - Consideration: $1.0 million
  - Closing: 2024-09-03
  source text: Lonafarnib Antiviral Asset Sale On August 1, 2024, the Company and Eiger InnoTherapeutics, Inc. (the “ Purchaser ”) entered into that certain Lonafarnib Asset Purchase Agreement, pursuant to which the Purchaser agreed to acquire all of the Company’s rights, title and interests in, to and under the assets and interests used in the business related to the development, manufacture and commercialization of certain lonafarnib antiviral products for $5.2 million, plus a portion of the cure costs with respect to assigned contracts and the assumption of specified liabilities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1305253/000119312524212606/0001193125-24-212606-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.